NCT02049515View on ClinicalTrials.gov

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

PHASE3CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

June 12, 2020

Study Completion Date

June 12, 2020

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

IPI-145

PI3K Inhibitor

DRUG

Ofatumumab

Monoclonal antibody

Trial Locations (69)

1000

Brussels

1023

Auckland

1083

Budapest

1090

Vienna

1122

Budapest

1130

Vienna

1200

Brussels

3000

Leuven

3002

East Melbourne

3058

Melbourne

4010

Linz

4032

Debrecen

4442

Palmerston North

4600

Wels

5042

Bedford Park

6725

Szeged

7400

Kaposvár

7624

Pécs

9000

Ghent

9024

Győr

9100

Sint-Niklaas

10032

New York

10065

New York

10707

Berlin

14033

Caen

20132

Milan

20162

Milan

22903

Charlottesville

26789

Leer

28033

Madrid

28050

Madrid

31008

Pamplona

33076

Bordeaux

33705

St. Petersburg

33916

Fort Myers

35033

Rennes

35128

Padua

37203

Nashville

44000

Nantes

45236

Cincinnati

47014

Meldola

47923

Rimini

48121

Ravenna

54511

Vandœuvre-lès-Nancy

63100

Clermont-Ferrand

63130

St Louis

73100

Lecce

80218

Denver

85025

La Roche-sur-Yon

87042

Limoges

89081

Ulm

93009

Bobigny

95107

Argenteuil

95124

Catania

92093-0698

La Jolla

02114

Boston

02115

Boston

07601

Hackensack

08903

New Brunswick

00133

Roma

08035

Barcelona

08036

Barcelona

08041

Barcelona

BH7 7DW

Bournemouth

LS9 7TF

Leeds

M20 4BX

Manchester

NG5 1PB

Nottingham

OX3 7JL

Oxford

SM2 5PT

Sutton

All Listed Sponsors
lead

SecuraBio

INDUSTRY

NCT02049515 - A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | Biotech Hunter | Biotech Hunter